Investor Relations

Upcoming Events

International Stroke Conference 2022

4th Chronic Kidney Disease Drug Development Summit (previously CKD3)

Most Recent Business Quarterly Update

View Q3 2021 Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

Investor Contact Information


DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447

Investor Relations

LifeSci Advisors, LLC
Timothy McCarthy, CFA
Managing Director, Relationship Manager
T: 212.915.2564

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456